

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

Summary of Main Points from the Meeting held on the 13th May 2013

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the April 2013 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Additions:

Adrenaline auto-injector (Jext®)

Decision: Approved. Tariff Included Medicine

Jext® is indicated for the emergency treatment of severe acute allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis for both paediatrics and adults.

Jext® will replace Epipen® on the formulary.

Switching from Epipen® to Jext® will confer financial benefit due to the 6 month longer shelf life of Jext® compared with Epipen®.

Pharmacy will arrange for training of staff and training material to support patient counselling during the switch over.

Individual funding requests

• **Interferon Gamma for TB (Approved - For noting)**

Interferon Gamma approved by the Pharmacoeconomic Board for a patient who remains TB smear positive despite quadruple therapy via DOT.

• **Infliximab for Erythrodermi Pityriasis (Approved - For noting)**

Infliximab approved by the Pharmacoeconomic Board for a patient with Erythrodermi Pityriasis.

Ex-panel

• **Pyrazinamide 500mg tablets & 500mg/5ml liquid (Licensed preparations) (Approved)**

To replace the unlicensed preparations.

Removals

• **Pyrazinamide 500mg tablets & 500mg/5ml liquid (Unlicensed preparations) (Approved)**

To be replaced by the licensed preparations

5. NICE Guidance on developing and updating local formularies

NICE Guidance on developing and updating local formularies

Decision: Noted

A status report was provided on the updated action plan as at May 2013.

6. Trust Medicines Policy

Review of membership skill mix against NPA Local decision-making competency framework

A summary was provided on the need for an assessment to be undertaken as good practice of the ability of the panel to meet the competency framework developed by the NPA to support the decision-making process relating to medicines. A decision was made for the assessment to be undertaken by DR and for this to be forwarded to panel members for consideration and comment. Results to be discussed at the Medicines Committee meeting in June.

Section 6. Controlled Drugs (CDs)

Decision: Approved / Approval pending

Updated to include:

- Change to the controlled drug status to PDE Type 5 inhibitors (e.g. sildenafil, tadalafil etc) from being treated as a Schedule 2 CD. Stock to be stored in the robot/CD room for security reasons.
- Change to the location of documentation of destruction of part used PCAs and epidurals to a designated page in the CD register to ensure standardisation across the Trust.
- New section added relating to illicit drugs. Approval pending comments from Tony Pritchard.

Appendix. Controlled Drugs Governance Arrangements

Decision: Approved

Updated to include details of the new Trust Accountable Officer for Controlled Drugs - Dr Zoe Penn who has replaced Dr Michael Anderson.

TMP - Section 2. Prescribing

Decision: Approved

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee

Medicines reconciliation updated to reflect "Professional standards for hospital pharmacy services" guidance from RPSGB and adult emergency standards AES.

TMP - Section 8. Administration

Decision: Not approved

Updated to include a requirement for the documentation of a double check at the point of when a syringe change occurs or there is a change in the administration rate during a continuous infusion. Requires further clarification on how double signing will operate in settings where regular changes are required e.g. Obstetrics and Intensive Care.

7. Shared Care Guidance

A summary was provided on the proposed plans for managing shared care arrangements across NWL. These include:

- The term "Shared care guidance" will be replaced by "Prescribing and drug monitoring guidance" (PDMG).
- A trust will take the lead on developing a particular PDMG.

The draft PDMG will be discussed at the NWL Medicines Management Pharmacy Network.

- The PDMG will then be embedded into the comments section in the formulary.
- Each trust will be responsible for disseminating information about any PDNG added to the formulary.

The panel agreed to these principles going forward

8. NICE Guidance

Nice Guidance March/April 2013

• **TA276 – Colistimethate for Cystic Fibrosis**

Tobramycin dry powder for inhalation (DPI) is recommended as an option for treating chronic pulmonary infection caused by *Pseudomonas aeruginosa* in people with Cystic Fibrosis in particular circumstances.

Not applicable to C&W

• **TA277 – Methylnaltrexone for Bowel Dysfunction**

NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care because no evidence submission was received from the manufacturer of the technology.

Not recommended for use

• **TA278 – Omalizumab for Asthma**

Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in people aged 6 years and older in particular circumstances.

Not applicable to C&W

• **TA279 – Vertebroplasty and kyphoplasty for Vertebral Fractures**

Percutaneous vertebroplasty, and percutaneous balloon kyphoplasty without stenting, are recommended as options for treating osteoporotic vertebral compression fractures.

Action: To confirm if applicable to C&W

• **TA280 – Abatacept for rheumatoid Arthritis**

Abatacept in combination with methotrexate is recommended as an option for treating rheumatoid arthritis in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate in particular circumstances.

Action: Note to added to local formulary

• **TA281 – Canakinumab for Gout**

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks because no evidence submission was received from the manufacturer of the technology

Not recommended for use

• **TA282 – Pirenidone for Idiopathic Pulmonary Fibrosis**

Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis in particular circumstances.

Not applicable to C&W

9. IVIG Update

The panel noted the IVIG report.

There were 12 IVIG issues in April 2013, with 4 new requests.

10. Items for Noting

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

- **2012-2013 Medicines related CQUINs Performance Report: NWL Integrated Formulary adherence audit results - Mar 2013**

Noted. The compliance rate for March 2013 was overall 93%. This was an audit of all issues of out-patient and discharge prescriptions. The result for each month in 2012/13 was consistently above 90%.

- **2012-2013 Medicines related CQUINs ACEi/ARB & statin audit - Quarter 4**

Noted. The compliance rate for March 2013 was overall 100%. The result for each month in 2012/13 was consistently 100%.

- **Improving Medicines Management – Analgesics**

Noted. Action plan compiled following a meeting to discuss an identified trend in reported clinical incidents concerning the appropriate and timely administration of analgesia.

Further action to be undertaken: Point of care audit to be undertaken. At a later stage it is anticipated that omitted and delayed doses will be a Safety Thermometer point prevalence audit going forward.

- **Summary of Pharmacy inspection by GPhC**

Noted

- **Guidance on the management of medicines excluded for National Tariff 2013-14**

Noted

- **CD Occurrence Report Q4 2012/13**

Noted

- **Drugs Sub-Committee Meeting minutes - Mar 2013**

Noted

- **NWL Red List - Mar 2013**

Noted

- **PGD Resister - May 2013**

Noted

- **NMP Register - May 2013**

Noted

- **MHRA Drug Safety Update - Apr 2013**

Noted

11. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee:

- Medicines Committee Summary Notes - April 2013

12. AOB

Nil

Date of the next meeting

Monday 10th June 2013, 8.00 – 9.00 Boardroom, Lower Ground Floor.

Closing date for papers: Friday 17th May 2013